However, given the difficulty of treatment, prevention of BMs should be the focus, especially among the high-risk groups, including patients with stage III/IV non-small cell lung cancer (NSCLC), HER2+ breast cancer, and melanoma. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.